Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01 clinical trials
Also written EXL01.
How each study uses Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 5
Hospices Civils de Lyon (1) · City of Hope Medical Center (1) · University Hospital, Lille (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Center Eugene Marquis (1) · Exeliom Biosciences (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01.
- Sep 2027First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerPhase 2 · GERCOR - Multidisciplinary Oncology Cooperative Group
Studies
Open first, then newest update. How each study uses Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk PatientsRecruitingPhase 1/2Hospices Civils de LyonNCT06306014Written as EXL01
- Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerRecruitingPhase 1City of Hope Medical CenterNCT07128680Written as Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01
- EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.RecruitingPhase 1/2University Hospital, LilleNCT06448572Written as EXL01
- First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerRecruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT06253611Written as EXL01
- Microbiota Modification for Immuno-oncology in Hepatocellular CarcinomaRecruitingPhase 2Center Eugene MarquisNCT06551272Written as EXL01
- EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's DiseaseTerminatedPhase 1Exeliom BiosciencesNCT05542355Written as EXL01